# Bezlotoxumab as Secondary Prophylaxis for C. Difficile in High-risk Hospitalized Patients Exposed to Antibiotics.

> **NCT03937999** · PHASE4 · TERMINATED · sponsor: **Montefiore Medical Center** · enrollment: 1 (actual)

## Conditions studied

- Clostridium Difficile

## Interventions

- **DRUG:** Bezlotoxumab

## Key facts

- **NCT ID:** NCT03937999
- **Lead sponsor:** Montefiore Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-08-30
- **Primary completion:** 2022-05-15
- **Final completion:** 2022-05-15
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Slow enrollment due to COVID19 , change in practice with standardized use of oral vancomycin prophylaxis
- **Last updated:** 2022-11-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03937999

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03937999, "Bezlotoxumab as Secondary Prophylaxis for C. Difficile in High-risk Hospitalized Patients Exposed to Antibiotics.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03937999. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*